Evidence map›Paper›PMID 40049930›Full record

ArticleJACC. Asia2025

A Membrane Modification Technique for Left Atrial Appendage Occlusion: A Multicenter Randomized Controlled Trial.

Youqi Fan, Dongxing Ma, Changqian Wang, Jun Luo, Zhiyu Ling, Shuyan Li, Xiaoping Peng, Zheng Zhang, Huimin Chu, Jianan Wang and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04429646 (A Prospective, Multicenter, Randomized, Active Controlled, Clinical Trial of the LAMax LAA Closure System Compared to the Watchman® LAAC Device for Subjects With Non-valvular Atrial Fibrillation to Reduce the Risk of Ischemic Stroke), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04429646 nacompletednot on this map

A Prospective, Multicenter, Randomized, Active Controlled, Clinical Trial of the LAMax LAA Closure System Compared to the Watchman® LAAC Device for Subjects With Non-valvular Atrial Fibrillation to Reduce the Risk of Ischemic Stroke

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2019 to 2021Enrolled236ConditionsNon-valvular Atrial FibrillationArmsPercutaneous left atrial appendage closure-LAMax, Percutaneous left atrial appendage closure-Watchman
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Youqi FanDepartment of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Dongxing MaDepartment of Cardiology, the Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Changqian WangDepartment of Cardiology, Shanghai Ninth People's Hospital, Shanghai, China.
Jun LuoDepartment of Cardiology, Ganzhou People's Hospital, Jiangxi, China.
Zhiyu LingDepartment of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shuyan LiDepartment of Cardiology, The First Hospital of Jilin University, Changchun, China.
Xiaoping PengDepartment of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zheng ZhangDepartment of Cardiology, The First Hospital of Lanzhou University, Lanzhou, China.
Huimin ChuDepartment of Cardiology, Ningbo First Hospital, Ningbo, China.
Jianan WangDepartment of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China; Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, China; Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou, China. Electronic address: wangjianan111@zju.edu.cn.
investigators in the present study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously pioneered a negatively ionized polyethylene terephthalate membrane method (the SMART technique) with the LAMax (test) occluder to reduce platelet adhesion and promote endothelialization.

objectivesThis study aimed to compare the safety and efficacy of the test occluder with the Watchman 2.5 device (control) in patients with nonvalvular atrial fibrillation to reduce stroke risk.

methodsOverall, 236 patients were randomly assigned (1:1) (open-label) to the test or control device for left atrial appendage occlusion (LAAO). The effectiveness endpoints included 12-month successful left atrial appendage (LAA) sealing with residual flow ≤5 mm and clinical success (composite of ischemic stroke, transient ischemic attack, and systemic embolism). Safety endpoints were also studied. A noninferiority margin of -7% was set between the devices.

resultsThe test device was noninferior to the control device for the effectiveness endpoints of successful LAA sealing (test 93.2% vs control 89.8%; P < 0.05) and clinical success (test 93.2% vs control 89.8%; P < 0.05). The 12-month safety endpoints were similar between the 2 devices. The device-related thrombus rates for the control device at the 3- and 12-month visits were 5.7% and 4.6%, respectively; no cases of device-related thrombus occurred with the test device.

conclusionsThis study suggests that transcatheter LAAO using the SMART technique may effectively and safely prevent stroke in patients with nonvalvular atrial fibrillation. Although further studies with larger sample sizes are needed, this novel technique may prevent device-related thrombus formation and has high potential for application in interventional therapies. (LAMax Vs. Watchman LAAC Device for Subjects With Non-valvular AF to Reduce the Risk of Stroke; NCT04429646).

Indexed as

anticoagulantatrial fibrillationdevice-related thrombusleft atrial appendagestroke

Identifiers

PMID40049930
PMCPMC11934047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.